Exscientia stock.

13 сент. 2021 г. ... After penning a major funding round earlier this year, the artificial intelligence-powered drug designer Exscientia ... Share. molecule ...

Exscientia stock. Things To Know About Exscientia stock.

Mar 27, 2023 · Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently down 14.9% so far this month. During the month of March, Exscientia PLC (ADR)’s stock price has reached a high of $7.11 and a low of $5.50. Over the last year, Exscientia PLC (ADR) has hit prices as high as $16.45 and as low as $4.09. Year to date ... Robert Ghenchev. Novo Holdings. Get in touch. Meet the Exscientia team of world-class scientists and leading pharmatech experts. We are driven by a passion for changing the world. Visit our site to discover more.Exscientia has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500.Legal Name Exscientia Ltd. Stock Symbol NASDAQ:EXAI. Company Type For Profit. Contact Email [email protected]. Phone Number +44-1865-818941. Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug …

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced that it has enrolled the first patient in its Phase 1/2 “ELUCIDATE” (GTAEXS617-001) study evaluating GTAEXS617 (‘617), Exscientia’s precision-designed CDK7 inhibitor, for the treatment of advanced solid tumours. The clinical trial will evaluate …Exscientia IPO price range is $20 and $22 a piece. How to Invest in Exscientia after the IPO date (opening price)? After the IPO you can buy Exscientia stocks via Freedom24. Or if you're from the US use a commission-free trading app like Webull on the first trading day. In what currency Exscientia IPO and post-IPO shares will be traded?

OXFORD, U.K., September 20, 2023--Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug ...According to 3 stock analysts, the average 12-month stock price forecast for Exscientia stock is $10, which predicts an increase of 62.07%. The lowest target is $7.00 and the highest is $13. On average, analysts rate Exscientia stock as a buy.

Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 5.38% so far this month. During the month of March, Exscientia PLC (ADR)’s stock price has reached a high of $7.11 and a low of $6.02. Over the last year, Exscientia PLC (ADR) has hit prices as high as $17.66 and as low as $4.09. Year to date, Exscientia ...Jun 20, 2023 · Exscientia Plc has an analyst consensus of Moderate Buy, with a price target consensus of $14.00. See the top stocks recommended by analysts >> EXAI market cap is currently $883.3M and has a P/E ... Public companies currently own 4.6% of Exscientia stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching ...Discover historical prices for EXAI stock on Yahoo Finance. View daily, weekly or monthly format back to when Exscientia plc stock was issued. ... Exscientia plc (EXAI) NasdaqGS - NasdaqGS Real ...Exscientia also has its eyes on up to $125 million in near-term milestones that form part of a potential $1.3 billion package. Sanofi originally made a smaller bet on Exscientia when it formed a ...

OXFORD, U.K.--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced a new collaboration with Merck KGaA, Darmstadt, Germany focused on the discovery of novel small molecule drug candidates across oncology, neuroinflammation and immunology. The multi-year collaboration will utilise Exscientia’s AI-driven precision …

Another exciting entity among innovation-driven biotech stocks to buy, Exscientia (NASDAQ:EXAI) bills itself as the world’s leading pharmatech. Per its website, Exscientia utilizes AI to ...

We would like to show you a description here but the site won’t allow us.Public companies currently own 4.6% of Exscientia stock. It's hard to say for sure but this suggests they have entwined business interests. This might be a strategic stake, so it's worth watching ...OXFORD, England & VIENNA, Austria, July 18, 2023--Exscientia plc (Nasdaq: EXAI) today announced the initiation of EXCYTE-1, a prospective observational study in ovarian cancer to investigate the ...Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Find real-time EXAI - Exscientia PLC stock quotes, company profile, news and forecasts from CNN Business.

Shares of Exscientia (EXAI 2.18%) ... The stock is up more than 38% so far this year. So what. Exscienta is an AI-driven precision medicine company that focuses on oncology therapies. The clinical ...A drug molecule "invented" by artificial intelligence (AI) will be used in human trials in a world first for machine learning in medicine. It was created by British start-up Exscientia and ...We are a creative, passionate and collaborative organisation dedicated to setting bold new standards in drug discovery and design. If you have the ingenuity, energy and ambition to help us change the world, we would love to hear from you. Open positions. At Exscientia, we combine the power of AI and human creativity to make safer and more ...EXS73565. MALT1. * Phase 3 may not be required if Phase 2 is registrational: PKC-theta is in a Phase 1 healthy volunteer study. Does not include Sumitomo Pharma programmes. Our pipeline demonstrates our ability to rapidly translate scientific concepts and patient-centric data into precision-designed therapeutic candidates.Oxford, U.K.-based Exscientia has multitarget collaborations with Bristol Myers Squibb and Sanofi but has seen investor enthusiasm wane since it went public two years ago, dragging its stock down ...

4 окт. 2021 г. ... The Oxford, U.K.-based company offered more than 13.8 million American depositary shares priced at $22 apiece, which was the top end of the ...

Cash inflows: For the first quarter 2023, Exscientia received $0.5 million in cash inflows from its collaborations as compared to $6.3 million during the first quarter 2022. Net operating cash flow and cash balance: For the three months ended March 31, 2023, net operating cash outflows were $53.7 million, in comparison to net operating cash ...Nov 21, 2023 · Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently down 0.37% so far this month. During the month of November, Exscientia PLC (ADR)’s stock price has reached a high of $6.32 and a low of $4.95. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ... Oxford, U.K.-based Exscientia has multitarget collaborations with Bristol Myers Squibb and Sanofi but has seen investor enthusiasm wane since it went public two years ago, dragging its stock down ...In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from ...Exscientia Plc engages in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of therapeutic compounds. The company was founded by Andrew L. Hopkins in 2012 and is headquartered in Oxford, the United Kingdom. EXAI - Exscientia Plc ADR - Stock screener for investors and traders, financial ...Exscientia has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Comparatively, Valneva has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500.Exscientia has raised a total of. $374.4M. in funding over 8 rounds. Their latest funding was raised on Jul 8, 2021 from a Grant round. Exscientia is registered under the ticker NASDAQ:EXAI . Their stock opened with $22.00 in its Oct 1, 2021 IPO. Exscientia is funded by 17 investors. Bill & Melinda Gates Foundation and Hongyou Investment are ...How much is Exscientia stock worth today? ( NASDAQ: EXAI) Exscientia currently has 124,511,492 outstanding shares. With Exscientia stock trading at $6.17 per share, the total value of Exscientia stock (market capitalization) is $768.24M. Exscientia stock was originally listed at a price of $27.10 in Oct 1, 2021.

EXS-21546 is a highly selective A 2A receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN ...

The Oxford Club’s Alexander Green has released a new (September 2023) presentation about what he believes is the “#1 AI stock.”. In the presentation, Alex Green says that the company he’s teasing could become the “most important AI company in the world” in the years ahead. And in the process, make lots of money for those who invest ...

OXFORD, England--(BUSINESS WIRE)-- Exscientia plc (Nasdaq: EXAI) today announced data from its Phase 1 healthy volunteer study of EXS-21546, its highly selective A 2A receptor antagonist co-invented and developed through a collaboration between Exscientia and Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, …The share price of Exscientia plc (EXAI) now. What analysts predict: $9.5. 52-week High/Low: $11.52 / $4.09. 50/200 Day Moving Average: $5.22 / $6.25. This figure corresponds to the Average Price over the previous 50/200 days. For Exscientia stocks, the 50-day moving average is the support level today. For Exscientia stocks, the 200 …In October 2021, Exscientia was floated on the Nasdaq stock market, raising $510 million, the largest initial public offering for a European biotech ever. From small beginnings, with just five staff, Exscientia now employs over 400 people.The consensus price target hints at a 76.1% upside potential for Exscientia PLC Sponsored ADR (EXAI). While empirical research shows that this sought-after metric is hardly effective, an upward ... This came just a few months after Recursion raised $436 million in an upsized IPO in April 2021 (Table 1). Exscientia, a pioneer in applying AI to small-molecule drug design, had a hefty IPO in ...How much is Exscientia stock worth today? ( NASDAQ: EXAI) Exscientia currently has 124,511,492 outstanding shares. With Exscientia stock trading at $6.17 per share, the total value of Exscientia stock (market capitalization) is $768.24M. Exscientia stock was originally listed at a price of $27.10 in Oct 1, 2021.Exscientia Stock Performance. Shares of NASDAQ EXAI opened at $6.17 on Monday. The business’s 50-day simple moving average is $5.38 and its 200-day simple moving average is $6.28. The company ...Jun 6, 2023 · Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 7.65% so far this month. During the month of June, Exscientia PLC (ADR)’s stock price has reached a high of $8.39 and a low of $6.70. Over the last year, Exscientia PLC (ADR) has hit prices as high as $16.45 and as low as $4.09. Year to date, Exscientia ... Dec 1, 2023 · 2012. 481. Andrew Hopkins. https://www.exscientia.ai. Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. The company offers end-to-end solution of artificial intelligence (AI) and technologies for target identification, drug candidate design, translational models, and ... Exscientia's existing partnerships include collaborations with Celgene, GSK, Roche, Sanofi and Evotec. ... This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the …Description. Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe and efficacious compounds for clinical ...

Exscientia PLC (ADR) Stock Price History. Exscientia PLC (ADR)’s price is currently up 22.35% so far this month. During the month of October, Exscientia PLC (ADR)’s stock price has reached a high of $6.02 and a low of $4.17. Over the last year, Exscientia PLC (ADR) has hit prices as high as $11.52 and as low as $4.09. Year to date ...TipRanks | Stock Market Research, News and Analyst Forecasts - TipRanks.comThe Exscientia plc stock prediction for 2025 is currently $ 2.59, assuming that Exscientia plc shares will continue growing at the average yearly rate as they did in the last 10 years. This would represent a -56.63% increase in the EXAI stock price.Instagram:https://instagram. free day trading platform10 year municipal bond ratewebull trade limitsget funded trading futures About Exscientia Stock Founded 10 years ago, Exscientia describes itself as a pharmatech company with an end-to-end AI-powered platform that leverages experimental technologies for identifying potential disease targets and then designing drugs that would be the most effective and safe.Sanofi will pay Exscientia $100 million in cash upfront, with Exscientia eligible to receive additional payments worth up to $5.2 billion in total if certain research and development milestones ... biggest kidney stonesinvest daily OXFORD, U.K., November 09, 2023 -- ( BUSINESS WIRE )--Exscientia plc (Nasdaq: EXAI): Recent advancements in the Company’s pipeline, collaborations and operations, as well as financial results ... stocks to buy in 2023 Legal Name Exscientia Ltd. Stock Symbol NASDAQ:EXAI. Company Type For Profit. Contact Email [email protected]. Phone Number +44-1865-818941. Exscientia is applying AI and big data processing to accelerate drug discovery and development. At the forefront of small molecule drug discovery. They are the first company to automate drug …A. Exscientia ( EXAI) does not have any upcoming earnings reports scheduled yet. The last reported earnings were for reported on November 9, 2023 for Q3 and the Actual Revenue was $10.8M, which ...Sanofi will pay Exscientia $100 million in cash upfront, with Exscientia eligible to receive additional payments worth up to $5.2 billion in total if certain research and development milestones ...